All-trans retinoic acid (ATRA) sensitizes BRCA1-proficient breast cancer to PARP inhibition by inhibiting Pin1 and destabilizing BRCA1, which could extend the use of PARP inhibitors 65. This evidence concerns the gene PARP1 and breast carcinoma.